CClinicalTrials.gg
RecruitingNCT07520344Updated Sep 21, 2026

Wearable Photoplethysmography for Non-invasive Hydration Assessment

An interventional study of Exercise in Hydration Status, sponsored by PepsiCo Global R&D. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-21.

Sponsored by PepsiCo Global R&D · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

Hydration status during exercise is often determined by measuring body mass change, fluid intake and urine output. However, obtaining these measurements can be an invasive, time-consuming process. Hydration status may be detectable by analyzing blood flow patterns of the superficial (just under the skin) blood vessels. Wearable devices are now abundant among the general population, and despite attempts from several groups, a hydration status metric based on noninvasive wearable device metrics has not been developed. With wearables, a light source connected to an optical sensor transmits and reflects light through the body. The light sensor detects absorption of the light based on wavelength measurements of the detected light. Absorption of specific wavelengths of light energy is dependent upon the amount of oxygenated blood in the vessels. When the vessels expand and relax, the amount of blood volume in the observed tissue increases and decreases potentially causing a shift in the photoplethysmography (PPG) wave detected by the wearable. The shift in the shape of the PPG wave may be detected in a way that indicates the relative change in tissue hydration levels. However, to our knowledge, no wrist worn device that utilizes PPG has been successfully able to predict hydration status. Therefore, this study aims to utilize photoplethysmography (PPG) technology in a wearable device to accomplish this approach to hydration monitoring.

02

Conditions studied

  • Hydration Status
03

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Study subject is 18-45 years of age, inclusive
  • Subject is male or female
  • If female, subject is not pregnant, planning to get pregnant, or currently breast feeding
  • Subject is willing to avoid alcohol consumption 24 hours prior to visit(s)
  • Able to speak, write, and read English
  • Provision of written consent to participate
  • Subject is not taking medication that may interfere with the study, as indicated on the general health questionnaire (GHQ)
  • Subject has no health conditions that would prevent completion of the trial, as indicated on the GHQ
  • Subject is willing to fast overnight (no food or beverage, only water, \~8- 10 hours)
  • Subject is willing to refrain from vigorous exercise for 24 hours
  • Subject is willing to eat the exact same food the day prior to each visit to the testing site
  • Subject is willing to undergo fluid restriction to induce dehydration
  • Subject is willing to wear a wrist worn wearable device for the duration of the study

Exclusion criteria

Exclusion Criteria:

  • Subject has participated or currently enrolled in a clinical trial within the past 30 days
  • Subject has participated in any PepsiCo trial within the past 3 months
  • Subject has a condition or is taking medication that the investigator believes would interfere with his/her ability to provide informed consent, comply with the study protocol, which might confound the interpretation of the study results, or put the person at undue risk, as indicated on the GHQ
  • Subject is employed by, or has a parent, guardian, or other immediate family member employed by a company that manufactures any products that compete with any Gatorade product. If subject is unsure if a company would be considered a competitor to Gatorade, they will be asked to please let the study investigator know the name of the other company and the nature of their relationship to that company before they sign the informed consent.
  • Subject has a health condition or is taking medication that can be worsened by fluid restriction, as indicated on the GHQ
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Other
    Euhydrated Group

    Water provided to account for sweat loss during exercise and to maintain hydration over the 24-hour period

    Other: Exercise

  • Experimental
    Dehydrated Group

    Fluid restriction during exercise and the remaining 24 hours

    Other: Exercise

Interventions

  • OtherExercise

    Perform stationary cycling exercise in the laboratory for 2 30- minute bouts at a standardized exercise intensity (wattage) that elicits 50-80% heart rate max determined by equation (208-(70% of age))

05

What researchers measure

Primary outcomes

  1. Wearable Sensr Data

    photoplethysmogram (PPG) waveform data- optical signals obtained from photoplethysmography, which measure blood volume changes in the microvascular bed of tissue.

    Time frame: Continuous data collection over 24 hours from start of exercise trial through completion of Day 2 measurements.

  2. Body Mass Change

    Time frame: Change in body mass during 60 min exercise bout and over 24 hours from baseline

Secondary outcomes

  1. Urine Specific Gravity

    au

    Time frame: Day 1: Baseline, post 1st and 2nd 30 min exercise sessions Day 2: 1st morning void collected at home and upon arrival at laboratory

  2. Urine Volume

    g

    Time frame: Day 1: Baseline, post 1st and 2nd 30 min exercise sessions Day 2: 1st morning void collected at home and upon arrival at laboratory

  3. Urine Color

    Scale of 1 (most hydrated) to 7 (most dehydrated)

    Time frame: Day 1: Baseline, post 1st and 2nd 30 min exercise sessions Day 2: 1st morning void collected at home and upon arrival at laboratory

  4. Sweat Rate

    \[Body mass loss (kg) + fluid intake (mL)\]/Duration of exercise (hr)

    Time frame: Throughout entire duration of 60 min exercise bout

  5. Fluid Intake

    mL

    Time frame: documented by subject on provided log for 24 hours prior to exercise and experimental trials. Exercise bouts- DEH group restricted from fluid intake. EUH group fluid measured over duration of exercise bout (60 minutes).

  6. Subjective Feelings of Thirst

    Categorical Thirst Scale, on a scale of 1 (Not thirsty at all) to 7 (very, very thirsty).

    Time frame: Day 1 & 2: Following 5 min of rest

  7. Heart Rate

    bpm

    Time frame: At medical screening to determine eligibility. Day 1: Prior to start of exercise bouts during 5 min rest and every 10 min throughout entire duration of each 60 min exercise trial. Day 2: During 5 min rest, prior to body weight measurement.

  8. Blood pressure

    systolic/diastolic (mmHg)

    Time frame: Medical Screening to determine eligibility

  9. Subject Demographics

    Age, Sex, Race, and Ethnicity

    Time frame: At baseline

  10. Dietary Intake

    Food intake logs

    Time frame: Completed for 24 hours prior to baseline and between visits.

  11. Standardized Exercise Intensity

    W

    Time frame: Every 10 min throughout entire duration of each 30 min exercise bout to reach 50-80% of heart rate max.

  12. Rate of Perceived Exertion

    Borg Scale, a scale of 6 (No exertion at all) to 20 (maximal exertion)

    Time frame: Every 10 min throughout entire duration of each 30 min exercise bout

06

Study locations

2 of 2 sites recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07520344
Lead sponsor
PepsiCo Global R&D
Responsible party
Sponsor
First posted
Apr 9, 2026
Start date
May 12, 2026
Primary completion
Sep 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Sep 21, 2026

Study contacts

Anthony Wolfe
Contact
anthony.wolfe@pepsico.com
574-315-5901

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion